Alina M Allen1, W Ray Kim2, Terry M Therneau3, Joseph J Larson3, Julie K Heimbach4, Andrew D Rule5. 1. Division of Gastroenterology and Hepatology Mayo Clinic, Rochester, MN, United States. 2. Division of Gastroenterology and Hepatology Stanford University, Stanford, CA, United States. Electronic address: wrkim@stanford.edu. 3. Division of Biomedical Statistics and Informatics Mayo Clinic, Rochester, MN, United States. 4. Division of Transplant Surgery Mayo Clinic, Rochester, MN, United States. 5. Division of Nephrology and Hypertension Mayo Clinic, Rochester, MN, United States.
Abstract
BACKGROUND & AIMS: The accuracy of creatinine-based estimated GFR (eGFR) in assessing the prevalence of chronic kidney disease (CKD) and associated mortality after liver transplantation (LTx) is unknown. Using measured GFR (mGFR) by iothalamate clearance, we determined the prevalence of the entire spectrum of renal dysfunction and the impact of CKD on mortality after LTx. METHODS: A database that prospectively tracks all LTx recipients at this academic transplant program from 1985 to 2012 was queried to identify all adult primary LTx recipients. Our post-LTx protocol incorporates GFR measurement by iothalamate clearance at regular intervals. A multistate model was used to assess the prevalence of CKD, kidney transplant, and death after LTx. Time-dependent Cox regression analysis was performed to evaluate the impact of mGFR and eGFR changes on survival. RESULTS: A total of 1211 transplant recipients were included. At the time of LTx, the median age was 54 years, 60% were male and 86% were Caucasian. At 25 years after LTx, 54% of patients died, 9% underwent kidney transplantation, whereas 7%, 21%, and 18% had mGFR >60, 59-30, and <30 ml/min/1.73 m(2) respectively. The risk of death increased when mGFR decreased below 30 ml/min/1.73 m(2): HR = 2.67 (95% CI = 1.80-3.96) for GFR = 29-15 ml/min/1.73 m(2) and HR = 5.47 (95% CI = 3.10-9.65) for GFR <15 ml/min/1.73 m(2). Compared to mGFR, eGFR underestimated mortality risk in LTx recipients with an eGFR of 30-90 ml/min/1.73 m(2). CONCLUSIONS: An overwhelming majority of LTx recipients develop CKD. The risk of death increases exponentially when GFR <30 ml/min/1.73 m(2). Creatinine-based eGFR underestimates the mortality risk in a large proportion of patients.
BACKGROUND & AIMS: The accuracy of creatinine-based estimated GFR (eGFR) in assessing the prevalence of chronic kidney disease (CKD) and associated mortality after liver transplantation (LTx) is unknown. Using measured GFR (mGFR) by iothalamate clearance, we determined the prevalence of the entire spectrum of renal dysfunction and the impact of CKD on mortality after LTx. METHODS: A database that prospectively tracks all LTx recipients at this academic transplant program from 1985 to 2012 was queried to identify all adult primary LTx recipients. Our post-LTx protocol incorporates GFR measurement by iothalamate clearance at regular intervals. A multistate model was used to assess the prevalence of CKD, kidney transplant, and death after LTx. Time-dependent Cox regression analysis was performed to evaluate the impact of mGFR and eGFR changes on survival. RESULTS: A total of 1211 transplant recipients were included. At the time of LTx, the median age was 54 years, 60% were male and 86% were Caucasian. At 25 years after LTx, 54% of patients died, 9% underwent kidney transplantation, whereas 7%, 21%, and 18% had mGFR >60, 59-30, and <30 ml/min/1.73 m(2) respectively. The risk of death increased when mGFR decreased below 30 ml/min/1.73 m(2): HR = 2.67 (95% CI = 1.80-3.96) for GFR = 29-15 ml/min/1.73 m(2) and HR = 5.47 (95% CI = 3.10-9.65) for GFR <15 ml/min/1.73 m(2). Compared to mGFR, eGFR underestimated mortality risk in LTx recipients with an eGFR of 30-90 ml/min/1.73 m(2). CONCLUSIONS: An overwhelming majority of LTx recipients develop CKD. The risk of death increases exponentially when GFR <30 ml/min/1.73 m(2). Creatinine-based eGFR underestimates the mortality risk in a large proportion of patients.
Authors: T Gayowski; N Singh; L Keyes; C F Wannstedt; M M Wagener; H Vargas; T Laskus; J Rakela; J J Fung; I R Marino Journal: Transplantation Date: 2000-02-15 Impact factor: 4.939
Authors: Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort Journal: N Engl J Med Date: 2013-09-05 Impact factor: 91.245
Authors: John C LaMattina; Joshua D Mezrich; Luis A Fernandez; Anthony M D'Alessandro; Arjang Djamali; Alexandru I Musat; John D Pirsch; David P Foley Journal: Clin Transplant Date: 2013-01-07 Impact factor: 2.863
Authors: Marcello Tonelli; Scott W Klarenbach; Anita M Lloyd; Matthew T James; Aminu K Bello; Braden J Manns; Brenda R Hemmelgarn Journal: Kidney Int Date: 2011-08-17 Impact factor: 10.612
Authors: T A Gonwa; M L Mai; L B Melton; S R Hays; R M Goldstein; M F Levy; G B Klintmalm Journal: Transplantation Date: 2001-12-27 Impact factor: 4.939
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Giuseppe Cullaro; Joseph F Pisa; Robert S Brown; Gebhard Wagener; Elizabeth C Verna Journal: Transplantation Date: 2018-05 Impact factor: 4.939
Authors: Martin-Walter Welker; Nina Weiler; Wolf Otto Bechstein; Eva Herrmann; Christoph Betz; Mark Schöffauer; Stefan Zeuzem; Christoph Sarrazin; Kerstin Amann; Oliver Jung Journal: J Nephrol Date: 2018-06-26 Impact factor: 3.902
Authors: Alina M Allen; W Ray Kim; Joseph J Larson; Colin Colby; Terry M Therneau; Andrew D Rule Journal: Transplantation Date: 2015-07 Impact factor: 4.939
Authors: Giuseppe Cullaro; Pratima Sharma; Jennifer Jo; Jasmine Rassiwala; Lisa B VanWagner; Randi Wong; Jennifer C Lai; John Magee; Aaron Schluger; Pranab Barman; Yuval A Patel; Kara Walter; Scott W Biggins; Elizabeth C Verna Journal: Liver Transpl Date: 2021-08-20 Impact factor: 5.799